Close
New

Medscape is available in 5 Language Editions – Choose your Edition here.

 

Denys-Drash Syndrome Clinical Presentation

  • Author: Agnieszka Swiatecka-Urban, MD; Chief Editor: Maria Descartes, MD  more...
 
Updated: May 27, 2014
 

History

Denys-Drash syndrome (DDS) symptoms related to nephropathy: Placental size, pregnancy, and delivery are usually normal. At onset (usually within the first year of life), typical symptoms are those of nephrotic syndrome (eg, edema, abdominal distention, recurrent infections). With the rapid decline of the glomerular filtration rate (GFR) and progression to ESRD, the following additional symptoms develop:

  • Decreased activity
  • Poor feeding and growth
  • Loss of developmental milestones
  • Nonspecific aches and pains

Denys-Drash syndrome symptoms related to Wilms tumor: Palpable abdominal mass is the most common manifesting symptom, noticed in 90% of children by a physician on routine physical examination or by the parent during routine care. Other symptoms include the following:

  • Abdominal distention
  • Abdominal pain
  • Hematuria
  • Weight loss
  • Poor feeding
  • Inguinal hernia
  • Acute abdomen
Next

Physical

Signs related to nephropathy: At onset, signs of nephrotic syndrome predominate (eg, generalized edema, ascites). Evidence of venous thrombosis occasionally may develop secondary to nephrotic syndrome. With the decline of GFR, severe hypertension becomes apparent. Pallor reflecting anemia develops. When ESRD ensues, the following signs develop secondary to renal osteodystrophy:

  • Decreased activity
  • Loss of developmental milestones
  • Decline in the growth rate
  • Skeletal abnormalities (similar to those of vitamin D-deficient rickets)

Signs related to Wilms tumor: A palpable abdominal mass, hematuria, and hypertension are the most common signs. Other findings may include the following:

  • Weight loss
  • Obstipation
  • Inguinal hernia
  • Acute surgical abdomen
  • Respiratory distress from pleural effusions
  • Signs of congestive heart failure (CHF)

Signs related to intersex disorders include the following:

  • Most individuals with Denys-Drash syndrome who carry the 46,XY or 46,XX/46,XY karyotype have male pseudohermaphroditism. The spectrum of anomalies of the external genitalia may include penoscrotal hypospadias with cryptorchidism, enlarged clitoris with labial fusion, bifid scrotum with palpable gonads, and micropenis.
  • Abnormalities of the internal reproductive organs in these individuals may include presence of the vagina and uterus, streak ovaries, and dysgenetic testes. Individuals with the 46,XX karyotype may have streak gonads but usually display a normal phenotype and are considered to have the incomplete form of Denys-Drash syndrome.
Previous
Next

Causes

More than 96% of individuals with a clinical diagnosis of Denys-Drash syndrome have been found to carry a mutation in the WT1 gene. The vast majority of these mutations are missense changes in exons 9 or 8, which encode for the zinc fingers 3 and 2, respectively.

The exon 9 amino acid, arginine-394, critical in the DNA binding activity of the WT1 protein, is considered a mutational hot spot for Denys-Drash syndrome. A mutation of arginine-394 was present in 14 of 30 patients with Denys-Drash syndrome in one review of the literature.

Increasing number of mutations in other exons have been described. Another review identified missense mutations in 30 patients and mutations that lead to premature chain termination (truncation mutations) in 66 patients. Patients with truncation mutations had high frequency of bilateral Wilms tumor compared with patients with missense mutations (52% vs. 17%, respectively), with a higher percentage of bilateral tumors in patients with truncations that occurred in the 5' half of the WT1 gene. Such mutations result in a WT1 protein that lacks a functional nuclear localization signal.

The mutant cytoplasmic WT1 protein is thought to sequester some of the wild-type WT1 protein in the cytoplasm, resulting in a reduced amount of nuclear WT1. Furthermore, other putative WT1 interacting partners may also be sequestered in the cytoplasm, where they cannot perform their normal function.

Mutation in a single allele of the WT1 gene is sufficient to produce nephropathy and intersex disorder. One hypothesis suggests the abnormal WT1 allele product interacts with the function of the unaffected wild-type WT1 allele in a dominant-negative fashion and changes its normal regulatory functions.

The vast majority of patients with Denys-Drash syndrome have male karyotype and present with a wide spectrum of gonadal abnormalities; conversely, individuals with Denys-Drash syndrome and female karyotype have less severe or no gonadal abnormalities. Note the following:

  • In patients with 46,XY, the KTS-negative isoform of the WT1 protein associates and achieves synergy with steroidogenic factor 1 (SF1). SF1, in turn, promotes expression of the gene-encoding müllerian inhibiting substance (MIS).
  • In addition, DAX1, a gene that directs ovarian development, antagonizes this synergy. In the presence of the WT1 mutations characteristic in Denys-Drash syndrome, the abnormal WT1 protein cannot associate with SF1, and testis development fails because of the decreased expression of MIS and the unopposed action of the DAX1 gene.
  • The degree to which the synergy between WT1 and SF1 is interrupted determines the severity of gonadal abnormalities in 46,XY individuals. In contrast, in 46,XX individuals, an intact WT1 gene has not been shown absolutely necessary for normal female development; these patients have less severe or no gonadal abnormalities.

Development of Wilms tumor in patients with Denys-Drash syndrome results from mutations in both alleles of the WT1 gene. According to the 2-hit genetic model, Wilms tumor is a consequence of 2 independent events that lead to loss of function of both alleles of the WT1 gene. A constitutional or germline mutation in a single allele of the WT1 gene (first hit) leads to persistence of an undifferentiated mesenchyme. A somatic mutation (second hit) or loss of heterozygosity in the second allele causes uncontrolled cell proliferation and Wilms tumor formation.

Previous
 
 
Contributor Information and Disclosures
Author

Agnieszka Swiatecka-Urban, MD FASN, Assistant Professor, Department of Pediatrics, Cell Biology and Physiology, University of Pittsburgh School of Medicine; Assistant Professor, Department of Nephrology, Children's Hospital of Pittsburgh

Agnieszka Swiatecka-Urban, MD is a member of the following medical societies: American Society of Nephrology, American Society of Pediatric Nephrology, International Society of Nephrology, Women in Nephrology

Disclosure: Received consulting fee from Mallinckrodt Pharmaceuticals for consulting.

Coauthor(s)

Prasad Devarajan, MD, FAAP Louise M Williams Endowed Chair in Pediatrics, Professor of Pediatrics and Developmental Biology, Director of Nephrology and Hypertension, Director of the Nephrology Fellowship Program, Medical Director of the Kidney Stone Center, Co-Director of the Institutional Office of Pediatric Clinical Fellowships, Director of Clinical Nephrology Laboratory, CEO of Dialysis Unit, Department of Pediatrics, Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine

Prasad Devarajan, MD, FAAP is a member of the following medical societies: American Heart Association, American Society of Nephrology, American Society of Pediatric Nephrology, National Kidney Foundation, Society for Pediatric Research

Disclosure: Received none from Coinventor on patents submitted for the use of NGAL as a biomarker of kidney injury for none.

Specialty Editor Board

Mary L Windle, PharmD Adjunct Associate Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Nothing to disclose.

Chief Editor

Maria Descartes, MD Professor, Department of Human Genetics and Department of Pediatrics, University of Alabama at Birmingham School of Medicine

Maria Descartes, MD is a member of the following medical societies: American Academy of Pediatrics, American College of Medical Genetics and Genomics, American Medical Association, American Society of Human Genetics, Society for Inherited Metabolic Disorders, International Skeletal Dysplasia Society, Southeastern Regional Genetics Group

Disclosure: Nothing to disclose.

References
  1. Nso Roca AP, Pena Carrion A, Benito Gutierrez M, et al. Evolutive study of children with diffuse mesangial sclerosis. Pediatr Nephrol. 2009 May. 24(5):1013-9. [Medline].

  2. Andrade JG, Guaragna MS, Soardi FC, et al. Clinical and genetic findings of five patients with WT1-related disorders. Arq Bras Endocrinol Metabol. 2008 Nov. 52(8):1236-43. [Medline].

  3. da Silva TE, Nishi MY, Costa EM, et al. A novel WT1 heterozygous nonsense mutation (p.K248X) causing a mild and slightly progressive nephropathy in a 46,XY patient with Denys-Drash syndrome. Pediatr Nephrol. 2011 Aug. 26(8):1311-5. [Medline].

  4. Furtado LV, Pysher T, Opitz J, et al. Denys-Drash syndrome with neonatal renal failure in monozygotic twins due to c.1097G>A mutation in the WT1 gene. Fetal Pediatr Pathol. 2011. 30(4):266-72. [Medline].

  5. Guaragna MS, Soardi FC, Assumpcao JG, et al. The novel WT1 gene mutation p.H377N associated to Denys-Drash syndrome. J Pediatr Hematol Oncol. 2010 Aug. 32(6):486-8. [Medline].

  6. Breslow NE, Collins AJ, Ritchey ML, et al. End stage renal disease in patients with Wilms tumor: results from the National Wilms Tumor Study Group and the United States Renal Data System. J Urol. 2005 Nov. 174(5):1972-5. [Medline].

  7. Children's Oncology Group. Long-term follow-up guidelines for survivors of childhood, adolescent, and young adult cancers. Mar 2006. Available at http://www.survivorshipguidelines.org/.

  8. Al-Hussain T, Ali A, Akhtar M. Wilms tumor: an update. Adv Anat Pathol. 2014 May. 21(3):166-73. [Medline].

  9. Auber F, Lortat-Jacob S, Sarnacki S, et al. Surgical management and genotype/phenotype correlations in WT1 gene-related diseases (Drash, Frasier syndromes). J Pediatr Surg. 2003 Jan. 38(1):124-9; discussion 124-9. [Medline].

  10. Call KM, Glaser T, Ito CY, et al. Isolation and characterization of a zinc finger polypeptide gene at the human chromosome 11 Wilms' tumor locus. Cell. 1990 Feb 9. 60(3):509-20. [Medline].

  11. Coppes MJ, Campbell CE, Williams BR. The role of WT1 in Wilms tumorigenesis. FASEB J. 1993 Jul. 7(10):886-95. [Medline].

  12. Coppes MJ, Huff V, Pelletier J. Denys-Drash syndrome: relating a clinical disorder to genetic alterations in the tumor suppressor gene WT1. J Pediatr. 1993 Nov. 123(5):673-8. [Medline].

  13. Dumoucel S, Gauthier-Villars M, Stoppa-Lyonnet D, et al. Malformations, genetic abnormalities, and Wilms tumor. Pediatr Blood Cancer. 2014 Jan. 61(1):140-4. [Medline].

  14. Eddy AA, Mauer SM. Pseudohermaphroditism, glomerulopathy, and Wilms tumor (Drash syndrome): frequency in end-stage renal failure. J Pediatr. 1985 Apr. 106(4):584-7. [Medline].

  15. Gessler M, Konig A, Bruns GA. The genomic organization and expression of the WT1 gene. Genomics. 1992 Apr. 12(4):807-13. [Medline].

  16. Habib R. Nephrotic syndrome in the 1st year of life. Pediatr Nephrol. 1993 Aug. 7(4):347-53. [Medline].

  17. Habib R, Loirat C, Gubler MC, et al. The nephropathy associated with male pseudohermaphroditism and Wilms' tumor (Drash syndrome): a distinctive glomerular lesion--report of 10 cases. Clin Nephrol. 1985 Dec. 24(6):269-78. [Medline].

  18. Heathcott RW, Morison IM, Gubler MC, et al. A review of the phenotypic variation due to the Denys-Drash syndrome-associated germline WT1 mutation R362X. Hum Mutat. 2002 Apr. 19(4):462. [Medline].

  19. Jadresic L, Leake J, Gordon I, et al. Clinicopathologic review of twelve children with nephropathy, Wilms tumor, and genital abnormalities (Drash syndrome). J Pediatr. 1990 Nov. 117(5):717-25. [Medline].

  20. Jensen JC, Ehrlich RM, Hanna MK, et al. A report of 4 patients with the Drash syndrome and a review of the literature. J Urol. 1989 May. 141(5):1174-6. [Medline].

  21. Kashtan CE. Glomerular disease. Semin Nephrol. 1999 Jul. 19(4):353-63. [Medline].

  22. Kessler O, Franco I, Jayabose S, et al. Is contralateral exploration of the kidney necessary in patients with Wilms tumor?. J Urol. 1996 Aug. 156(2 Pt 2):693-5. [Medline].

  23. Kist-van Holthe JE, Ho PL, Stablein D, Harmon WE, Baum MA. Outcome of renal transplantation for Wilms' tumor and Denys-Drash syndrome: a report of the North American Pediatric Renal Transplant Cooperative Study. Pediatr Transplant. 2005 Jun. 9(3):305-10. [Medline].

  24. Koziell A, Grundy R. Frasier and Denys-Drash syndromes: different disorders or part of a spectrum?. Arch Dis Child. 1999 Oct. 81(4):365-9. [Medline].

  25. Kucinskas L, Rudaitis S, Pundziene B, Just W. Denys-Drash syndrome. Medicina (Kaunas). 2005. 41(2):132-4. [Medline].

  26. Little M, Holmes G, Bickmore W, et al. DNA binding capacity of the WT1 protein is abolished by Denys-Drash syndrome WT1 point mutations. Hum Mol Genet. 1995 Mar. 4(3):351-8. [Medline].

  27. Little S, Hanks S, King-Underwood L, et al. A WT1 exon 1 mutation in a child diagnosed with Denys-Drash syndrome. Pediatr Nephrol. 2005 Jan. 20(1):81-5. [Medline].

  28. Mesrobian HG. Wilms tumor: past, present, future. J Urol. 1988 Aug. 140(2):231-8. [Medline].

  29. Motoyama O, Arai K, Kawamura T, et al. Clinical course of congenital nephrotic syndrome and Denys-Drash syndrome in Japan. Pediatr Int. 2005 Dec. 47(6):607-11. [Medline].

  30. Mueller RF. The Denys-Drash syndrome. J Med Genet. 1994 Jun. 31(6):471-7. [Medline].

  31. Pritchard-Jones K. The Wilms tumour gene, WT1, in normal and abnormal nephrogenesis. Pediatr Nephrol. 1999 Sep. 13(7):620-5. [Medline].

  32. Rauscher FJ. The WT1 Wilms tumor gene product: a developmentally regulated transcription factor in the kidney that functions as a tumor suppressor. FASEB J. 1993 Jul. 7(10):896-903. [Medline].

  33. Royer-Pokora B, Beier M, Henzler M, et al. Twenty-four new cases of WT1 germline mutations and review of the literature: genotype/phenotype correlations for Wilms tumor development. Am J Med Genet A. 2004 Jun 15. 127(3):249-57. [Medline].

  34. Rudin C, Pritchard J, Fernando ON, Duffy PG, Trompeter RS. Renal transplantation in the management of bilateral Wilms' tumour (BWT) and of Denys-Drash syndrome (DDS). Nephrol Dial Transplant. 1998 Jun. 13(6):1506-10. [Medline].

  35. Sanpakit K, Triwatanawong J, Sumboonnanonda A. Long-term outcome in pediatric renal tumor survivors: experience of a single center. J Pediatr Hematol Oncol. 2013 Nov. 35(8):610-3. [Medline].

  36. Schumacher V, Scharer K, Wuhl E, et al. Spectrum of early onset nephrotic syndrome associated with WT1 missense mutations. Kidney Int. 1998 Jun. 53(6):1594-600. [Medline].

  37. Schumacher V, Schneider S, Figge A, et al. Correlation of germ-line mutations and two-hit inactivation of the WT1 gene with Wilms tumors of stromal-predominant histology. Proc Natl Acad Sci U S A. 1997 Apr 15. 94(8):3972-7. [Medline].

  38. Schumacher V, Thumfart J, Drechsler M, et al. A novel WT1 missense mutation presenting with Denys-Drash syndrome and cortical atrophy. Nephrol Dial Transplant. 2006 Feb. 21(2):518-21. [Medline].

  39. Swiatecka-Urban A, Mokrzycki MH, Kaskel F, et al. Novel WT1 mutation (C388Y) in a female child with Denys-Drash syndrome. Pediatr Nephrol. 2001 Aug. 16(8):627-30. [Medline].

 
Previous
Next
 
Gross nephrectomy specimen shows a Wilms tumor pushing the normal renal parenchyma to the side.
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.